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Abstract
Introduction Post-traumatic stress disorder (PTSD)
is associated with an increased risk of dementia.
Individual epidemiological studies have controlled for
several confounders of the relationship between PTSD
and increased dementia risk, yet particular risk factors
underlying this relationship have not been determined.
This systematic review protocol aims to identify risk and
protective factors of dementia among adults with PTSD.
Methods and analysis We will conduct an electronic
search of the databases: PubMed, CINAHL, PsychINFO, The
Cochrane Library, Scopus and ProQuest Dissertation and
Theses Global. After screening the studies, quantitative
synthesis will be performed, if possible. Otherwise, a
narrative synthesis will be performed. We will include
randomised controlled trials and other types of research
evidence including longitudinal cohort studies. Strength
of evidence will be assessed using the Grading of
Recommendations, Assessment, Development and
Evaluations method. Examples of variables that will
be extracted are: year of PTSD diagnosis, comorbid
conditions, health behaviours, pharmacological treatments
and year of mild cognitive impairment or dementia
diagnosis. We developed this systematic review protocol
according to the Preferred Reporting Items for Systematic
Review and Meta-Analysis Protocols 2015 statement.
Ethics and dissemination The proposed study will
not collect individual-level data and, therefore, does not
require ethical approval. Results of this study will provide
current evidence on risk and protective factors of dementia
in adults with PTSD. Findings will be disseminated in peer-
reviewed publications and conference presentations.
PROSPERO registration number CRD42019128553.

Introduction
Post-
traumatic stress disorder (PTSD) is a
psychiatric syndrome that may develop in
individuals who have experienced a traumatic event1 (eg, war, sexual assault, accident
or environmental catastrophe) resulting in
symptoms of intrusive thoughts, avoidance of
trauma-related stimuli, negative alterations in
cognition or mood and changes in arousal.2
PTSD is characterised clinically by four groups
of related symptoms, also known as ‘symptom
clusters’, including: (1) intrusive thoughts

Strengths and limitations of this study
►► This systematic review will provide a comprehen-

sive search of the literature regarding risk and
protective factors of dementia among adults with
post-traumatic stress disorder (PTSD).
►► Experts in the field of cognitive decline, mild cognitive impairment, all-type dementia and PTSD developed and guided the search strategy.
►► An exhaustive search of multiple databases (ie,
PubMed, CINAHL, PsychINFO, The Cochrane Library,
Scopus and ProQuest Dissertation and Theses
Global) will be performed to ensure a comprehensive review, yet, potentially relevant articles from
other/additional databases may be missed.
►► Given that this review will be restricted to observational studies with 300 or more participants and
randomised controlled trials with 50 or more participants, relevant studies with important evidence may
be missed, for example, from studies with smaller
samples.
►► Another potential limitation may be that a meta-
analysis may not be conducted due to included studies being insufficiently homogenous, in which case a
narrative approach will be used.

(eg, feelings of re-
experiencing the event,
memories, dreams or flashbacks), (2) avoidance of trauma-related stimuli (eg, distressing
internal reminders such as thoughts, memories or feelings and distressing external
reminders such as people, places, conversations or objects), (3) negative alterations in
cognition or mood (eg, inability to remember
aspects of the traumatic event, negative
beliefs about self or others, persistent negative emotional state, feelings of detachment
or anhedonia) and (4) changes in arousal
(eg, irritable or angry outbursts, exaggerated
startle response, hypervigilance, problems
concentrating, sleep disturbance).2 Overall,
about 8.6 million US adults or 5.7% of the
population, aged 18–64 years, are diagnosed
with PTSD at some point in their lifetime.3 4
Research over the last decade has indicated
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early as mid-life, alterations in the brain are detectable by
imaging and other biomarkers18–20 introducing a potential opportunity for targeting modifiable risk and protective factors of dementia. However, the implementation of
screening and detection of cognitive decline in the PTSD
population as a means to facilitate early detection and
delay or prevention of dementia is another area in need
of research.
Researchers in the field of geriatric mental health
have identified several gaps in the care of older adults
with PTSD. Relative to younger adults, PTSD among
older adults is under-identified, under-treated and under-
researched.21 Furthermore, conventional evidence-based
PTSD treatments do not specifically focus on maintaining cognitive health. Given the increased prevalence
of dementia in the PTSD population in conjunction
with the fact that brain changes associated with cognitive decline start long before symptoms are evident,22 an
assessment of risk and protective factors could be used
by clinicians to augment PTSD treatment of middle-aged
adults in service of supporting cognitive health. Thus, the
overarching research question to be addressed is: ‘What
are risk and protective factors of dementia among adults
with PTSD?’
Objectives
This systematic review aims to critically appraise the
research on risk and protective factors of MCI/dementia
among adults with PTSD. Potential and anticipated
known comorbidities of
risk factors may include well-
PTSD, such as major depressive disorder,23 substance
use disorder,24 obesity25 and other associated genetic or
biological factors (ie, APOE genotype26 or female sex,27
respectively). Potential and anticipated protective factors
may include cognitive training or physical exercise.
Several of the aforementioned factors, among others,
are also associated with risk and prevention of dementia,
respectively.28–36 Therefore, the following two questions
will be addressed within a comparative context. Among
adults with PTSD, comparisons will be made between
those who did and did not develop MCI or dementia.
1. What are the recency, severity and duration of PTSD
exposure?
2. What is the exposure (dose, frequency, duration) of
previously identified risk and protective factors of
dementia?
Methods and analysis
Protocol and registration
This systematic review will be based on the approach
proposed by Joanna Briggs Institute37 and will build on
a prior systematic review of risk and protective factors for
dementia among the general population.10 37 The former
describes an approach toward systematic reviews, in which
a search is conducted for the ‘best available’ evidence.
The search strategy will be guided by the Preferred
Reporting Items for Systematic Review and Meta-Analysis
Lawrence KA, et al. BMJ Open 2020;10:e035517. doi:10.1136/bmjopen-2019-035517
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that a subset of individuals with PTSD is at greater risk for
developing all-type dementia.
Epidemiological evidence from studies of military
veterans5–7 and civilians8 9 has revealed that individuals
with PTSD have up to a fourfold greater risk of developing dementia than those without PTSD. However, it
remains unclear how PTSD leads to cognitive decline
and development of dementia. Within the general population, experts have identified several protective factors
associated with decreased dementia risk (eg, physical
activity, cognitive training, Mediterranean diet and vegetable intake).10 Such health behaviours may be more
common in adults with PTSD who do not develop mild
cognitive impairment (MCI) or dementia. Conversely,
factors associated with increased dementia risk, such as
genetic factors (eg, being homozygous for APOE ε4),
negative health behaviours (eg, tobacco use), psychiatric
disorders (eg, major depressive disorder), use of certain
pharmaceutical medications (eg, benzodiazepines) and
medical history (eg, stroke),11 may occur more frequently
in persons with PTSD who develop MCI or dementia.
However, it is also possible that PTSD confers neurobiological changes that contribute to the pathogenesis of dementia. While an association between PTSD
and impaired cognitive performance has been established,12–16 whether the cognitive effects of PTSD symptoms are mechanistically linked to the later development
of dementia is a significant gap in knowledge. In prior
retrospective cohort research on dementia incidence in
veterans with and without PTSD that controlled for several
confounding factors, findings indicated that a history of
head injury, substance misuse and clinical depression
were not responsible for the increased dementia risk in
persons with PTSD.6 Interestingly, a prospective cohort
study of World Trade Center first-responders who developed PTSD revealed that the intrusive thoughts, symptom
cluster of PTSD, was consistently predictive of cognitive
impairment 14 years later.17 This finding suggests that
exposure to PTSD itself may be a risk factor for dementia.
It remains unclear, however, which particular risk factors
account for the increased risk of dementia in the PTSD
population. Addressing this knowledge gap, we will
examine exposure to PTSD symptoms and previously
identified risk and protective factors associated with MCI
and all types of dementia among those with PTSD.
In a conceptualisation of cognition as a continuum
of indiscrete, overlapping degrees of functional ability,
normal cognition would sit at the left end, followed
by cognitive decline, MCI, and non-
specific dementia
and Alzheimer’s disease (AD) at the right end of the
continuum. Experts consider some degree of cognitive
decline as a normal part of the ageing process. MCI is set
apart from normal age-related cognitive decline in that
the degree of decline is greater than expected, considering the person’s age and educational background, yet
impairment is not severe enough to meet criteria for a
diagnosis of dementia. Extant research on the stages of
cognitive decline leading to dementia indicates that as

Open access

Search for and identification of studies
The following databases will be searched: PubMed,
CINAHL, PsychINFO, The Cochrane Library and Scopus.
Additionally, we will search ProQuest Dissertations and
Theses Global for grey literature and unpublished studies.
We will limit our literature search to the English language
and human subjects. To guarantee literature satisfaction,
the references of included articles, identified through the
search, will be scanned.
Eligibility criteria
Studies on adults, with an average age of 50 years and older
at follow-up, who have been diagnosed with PTSD will be
included, given that neurodegenerative changes can be
observed before the age of 60.39 40 Because the identified
problem is the increased prevalence of dementia in older
adults with PTSD, comparators are adults aged 50 years
or over with PTSD (current or past) who do not develop
MCI or dementia. All racial and ethnic populations will
be considered.
Epidemiological findings have shown that chronic
stress and PTSD are both associated with an increased
incidence of different types of dementia.1 6 7 Therefore, this study will assess risk and protective factors
for MCI and all frequent/common causes of dementia
of all possible aetiologies, including senile dementias,
vascular dementia, AD, frontotemporal dementia,
Lewy body dementia and dementia not otherwise specified. This review will consider observational longitudinal cohort studies with 300 or more participants and
randomised controlled trials (RCTs) with 50 or more
participants, in order to include studies with sufficient
statistical power.37 In addition, for observational studies,
documentation of cognitive changes over at least 1 year
will be required for studies on MCI, to provide time for
the occurrence of clinically meaningful change.10 37 Two
years will be required for studies of all types of dementia,
including AD10 37 because of the lengthy prodromal
phase associated with dementia, especially AD. The
study outcomes will be a diagnosis of MCI or any type of
dementia, using acceptable standards. Given that PTSD
was accepted as a disorder and added to the Diagnostic
and Statistical Manual of Mental Disorders by the American Psychiatric Association in 1980,41 this systematic
review will consider any studies published from 1980
until 29 February 2020.
Lawrence KA, et al. BMJ Open 2020;10:e035517. doi:10.1136/bmjopen-2019-035517

Patient and public involvement
There was no patient or public involvement in the development of this study protocol.
Study selection and data abstraction
Using Covidence software42 and following the protocol
of Williams and colleagues,37 two reviewers with a third
tie-breaker reviewer will autonomously screen the titles
and abstracts yielded by the searches against the inclusion and exclusion criteria. Articles meeting the inclusion
criteria will subsequently undergo a full-text screening
performed by three reviewers. The three reviewers will
read each article and, based on this screening, render
a decision regarding which articles meet the inclusion
criteria. Disagreements will be resolved by consensus. The
review will be completed by 15 December 2020.
Data collection process and data items
Data extraction will be performed in duplicate and data
will be input into evidence tables in Excel, modelled
on the format of Williams and colleagues.37 The data
elements to be extracted include descriptors to assess
applicability, quality elements, intervention and exposure details, and outcomes. More specifically, the data
items will include: details about the timing of diagnosis
and duration of follow-up for PTSD, MCI and dementia
diagnoses and other cognitive outcomes; assessment/
diagnostic instruments used for PTSD and all cognitive outcomes; PTSD total and symptom cluster severity
scores; participant characteristics such as average age,
sex, race and education; study methodology including
sample size and study design; potential predictor factors
(eg, APOE genotype, prisoner of war status, pharmaceutical medications, cognitive training interventions and
health behaviours); study findings (eg, ORs and HRs)
and author conclusions. Disagreements between the two
reviewers will be resolved by consensus or by obtaining a
third reviewer’s opinion should the two reviewers fail to
reach consensus.
Assessment of study bias
Recommendations from Grading of Recommendations,
Assessment, Development and Evaluations will be followed
to allow assessment of risk-of-bias, imprecision, inconsistency, indirectness, publication bias, magnitude of effect,
dose–response gradient and residual confounding.43 This
approach gives a preliminary score of low to observational studies and high to RCTs.37 This preliminary score
can be upgraded by a thorough study design, constancy,
accuracy and other criteria as described by Williams and
colleagues.37
Analysis
If studies are of sufficient homogeneity regarding participants, interventions and outcomes, a meta-analysis will be
conducted.44 In accordance with the guidelines for quantitative synthesis of systematic review evidence,45 a tabular
summary of findings will be created. This table will include
extracted variables, information regarding the quality of
3
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Protocols (PRISMA-P)38. PRISMA-P is a search protocol
for systematic reviews and meta-analyses, which includes
an evidence-
based minimum number of items for
reporting. The search strategy (see online supplementary
appendix A) aims to locate both published and unpublished studies, as well as grey literature. Medical subject
headings and text words related to PTSD, cognitive
decline, MCI, dementia, and risk and protective factors
(based on a prior systematic review by Plassman and
colleagues10) were used to develop a search strategy.

Open access

Ethics and dissemination
The proposed study will not collect individual-level data
and, therefore, does not require ethical approval. The
results of this systematic review will provide the most up
to date literature synthesis of risk and protective factors
of dementia in adults with PTSD. Results will be disseminated through peer-reviewed publications and presentations at relevant national and international conferences.

Discussion
In the USA, one-
third of seniors die with dementia.
Annually, dementia-
related care costs have reached
US$290 billion.52 Epidemiological research has revealed
that PTSD is associated with increased risk for dementia.
Even after controlling for comorbidities (eg, head injury)
and other risk factors (eg, smoking), military veterans,5 6
first-responders,17 and civilians8 9 with PTSD showed an
approximately twofold5 and fourfold9 greater risk of developing all-type dementia, respectively.
While it has been well established that PTSD is associated with impaired cognitive performance,12–16 whether
4

the neurobiological changes associated with PTSD
account for increased dementia risk is a significant gap in
knowledge. This systematic review will provide a comprehensive search of the literature regarding risk and protective factors of dementia among adults with PTSD.
In the case of AD, early alterations in the brain can be
detected by imaging and other biomarkers,18–20 creating
the potential opportunity for being able to target modifiable risk and protective factors of Alzheimer’s dementia.
Implementation of screening and detection of cognitive
decline to facilitate early detection and delay or prevention of MCI/non-specific dementia in the PTSD population is another area in need of research.
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